Orthofix Announces Full Market Launch of Opus Mg Set – A Curable Magnesium Bone Filler for Orthopedic Procedures | Business
LEWISVILLE, Texas – (BUSINESS WIRE) – Sep 21, 2021–
Orthofix Medical Inc. (NASDAQ: OFIX), a global medical device company specializing in spine and orthopedics, today announced the full market launch of Set of mg Opus ™ osteoconductive scaffolding, a synthetic magnesium-based bone filler for orthopedic procedures.
This press release features multimedia. See the full version here: https://www.businesswire.com/news/home/20210921005189/en/
Image of the Orthofix Opus Mg set in injectable form. (Photo: Business Wire)
Opus Mg Set provides a procedure specific solution for orthopedic fracture care and trauma applications by filling voids or non-structural bone gaps during surgery. Available in both moldable and injectable form, Opus Mg Set provides immediate compressive strength at the surgical site after implantation. When injected or placed into voids or bone spaces, Opus Mg Set forms a supportive scaffold to help facilitate the natural process of bone healing.
“We are delighted to add the Opus Mg Set Osteoconductive Scaffolding to our comprehensive portfolio of biological solutions,” said Jon Serbousek, President and CEO of Orthofix. “Opus Mg Set is another example of our commitment to innovative biological solutions that will meet the needs of our valued surgeon customers and their patients. “
Opus Mg Set is a synthetic solution based on magnesium. Magnesium phosphate crystallizes to give thixotropic properties and high compressive strength. Additionally, magnesium is important in bone healing as it promotes the proliferation of osteogenic cells, improves new bone formation, and stimulates protein for bone regeneration. Preclinical studies with Opus Mg Set have shown greater than 80% bone turnover in 26 weeks.
For those attending the American Orthopedic Foot & Ankle Society Annual Meeting in Charlotte, NC, please visit Orthofix booth # 414 to learn more about the Opus Mg Set Osteoconductive Scaffolding.
Orthofix Medical Inc. is a global medical device focused on the spine and orthopedics. The company’s mission is to provide innovative, quality-driven solutions in partnership with healthcare professionals to improve the lives of patients. Based in Lewisville, Texas, Orthofix orthopedic and spinal products are distributed in more than 60 countries through the company’s sales representatives and distributors. For more information, please visit www.Orthofix.com.
This communication contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, regarding our business and financial prospects, which are based on about our current beliefs, assumptions, expectations, estimates, forecasts and projections. In some cases, you can identify forward-looking statements by words such as “may”, “will”, “should”, “expects”, “plans”, “anticipates”, “believes”, “intention” , “Predicted”, “potential” or “continue” or any other comparable terminology. These forward-looking statements are not guarantees of our future performance and involve risks, uncertainties, estimates and assumptions that are difficult to predict, including the risks described in part I, item 1A under the heading Risk factors in our report. annual on Form 10-K for the fiscal year ended December 31, 2020 (the “Form 10-K 2020”). In addition to the risks described therein, factors that could cause or contribute to such differences may include, but are not limited to: the risk that surgeons may be slow to adopt the Opus Mg Set osteoconductive scaffold; the risk that future patient studies or clinical experience and data may indicate that treatment with the Opus Mg Set osteoconductive scaffold does not improve patient outcomes as much as previously believed, or calls into question the benefits of its use for patients, hospitals and surgeons; the risk that the product will not perform as intended and therefore not achieve commercial success; the risk that competitors will develop higher quality products or occupy a more important position in the market allowing a more successful commercialization; the risk that insurers will refuse to reimburse healthcare providers for the use of our products.
This list of risks, uncertainties and other factors is not complete. We discuss in more detail some of these matters, as well as certain risk factors that could affect our business, financial condition, results of operations and prospects, in reports that we file from time to time with the Commission. SEC, which are available for reading at www.sec.gov. Some or all of the forward-looking statements we make may prove to be incorrect (due to inaccurate assumptions that we make or otherwise), and our results and actual results may differ materially from those expressed in such forward-looking statements. You should not place undue reliance on these forward-looking statements. In addition, any forward-looking statement speaks only as of the date hereof, unless it is specifically indicated that it is made on a different date. We assume no obligation to update, and expressly disclaim any obligation to update, our forward-looking statements, whether as a result of circumstances or events occurring after the date hereof, new information or otherwise.
View source version on businesswire.com:https://www.businesswire.com/news/home/20210921005189/en/
CONTACT: Alexa Huerta
Phone 214 937 3190
[email protected] Denise Landry
Phone 214 937 2529
KEYWORD: TEXAS UNITED STATES NORTH AMERICA
INDUSTRY KEYWORD: BIOTECHNOLOGY SURGERY MEDICAL DEVICES HEALTH PHYSICAL THERAPY
SOURCE: Orthofix Medical Inc.
Copyright Business Wire 2021.
PUB: 09/21/2021 7:00 a.m. / DISC: 09/21/2021 7:02 a.m.
Copyright Business Wire 2021.